Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPension (IS)Profit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Harvard Bioscience (HBIO) Research & Development (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Research & Development for 16 consecutive years, with $2.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development fell 16.95% to $2.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $9.0 million, a 20.11% decrease, with the full-year FY2024 number at $10.4 million, down 11.54% from a year prior.
  • Research & Development was $2.1 million for Q3 2025 at Harvard Bioscience, down from $2.2 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $3.5 million in Q2 2022 to a low of $2.1 million in Q3 2025.
  • A 5-year average of $2.7 million and a median of $2.8 million in 2023 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: surged 42.38% in 2021, then fell 26.1% in 2024.
  • Harvard Bioscience's Research & Development stood at $3.0 million in 2021, then decreased by 3.46% to $2.8 million in 2022, then increased by 10.57% to $3.2 million in 2023, then dropped by 26.1% to $2.3 million in 2024, then dropped by 8.42% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Research & Development are $2.1 million (Q3 2025), $2.2 million (Q2 2025), and $2.3 million (Q1 2025).